Related Experiment Videos
Long-term lithium treatment and thyroid antibodies: a controlled study
Christopher Baethge1, Holger Blumentritt, Anne Berghöfer
1Department of Psychiatry, Bipolar and Psychotic Disorders Program, Harvard Medical School, McLean Division of Massachusetts General Hospital, Belmont, Mass., USA.
Journal of Psychiatry & Neuroscience : JPN
|December 6, 2005
Summary
Long-term lithium treatment for affective disorders did not increase thyroid autoimmunity. This study found no significant difference in thyroid autoantibodies between patients on lithium and control groups.
Area of Science:
- Endocrinology
- Psychiatry
- Immunology
Background:
- Lithium is a common treatment for affective disorders.
- The link between lithium and thyroid dysfunction, specifically thyroid autoimmunity, is debated.
- Understanding this relationship is crucial for patient management.
Purpose of the Study:
- To investigate the prevalence of thyroid autoantibodies in patients with affective disorders on long-term lithium therapy.
- To compare these findings with age- and sex-matched controls without psychiatric disorders.
Main Methods:
- Cross-sectional study of 100 patients with affective disorders on lithium for ≥6 months.
- 100 age- and sex-matched controls without psychiatric disorders were included.
- Serum levels of thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb), and TSH receptor antibodies (TRAb) were measured.
Main Results:
- Thyroid peroxidase antibodies (TPOAb) were detected in 7% of patients and 11% of controls.
- Thyroglobulin antibodies (TgAb) were detected in 8% of patients and 15% of controls.
- TSH receptor antibodies (TRAb) were not detected in either group.
Conclusions:
- Long-term lithium treatment in patients with affective disorders did not elevate the prevalence of thyroid autoimmunity.
- The study suggests lithium itself may not be a primary driver of thyroid autoimmunity.
- Further research may explore other contributing factors to thyroid dysfunction in this population.